Qual é o preço para Galmed Pharmaceuticals Ltd. (GLMD)

O preço para Galmed Pharmaceuticals Ltd. (GLMD) é $0.5225

Qual é a capitalização de mercado para Galmed Pharmaceuticals Ltd. (GLMD)

A capitalização de mercado para Galmed Pharmaceuticals Ltd. (GLMD) é $4.32M

Galmed Pharmaceuticals Ltd. (GLMD) Desdobramentos de Ações

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.

Ano	Desdobramento	Multiplicador	Multiplicador cumulativo
Não há dados suficientes para as datas fornecidas.

Ano

Desdobramento

Multiplicador

Multiplicador cumulativo

Não há dados suficientes para as datas fornecidas.

Empresa	Número de desdobramentos de ações	Multiplicador cumulativo	País
Vertex Pharmaceuticals Incorporated VRTX.US	1	x2	US
Argenx SE ARGX.US	0	-	NL
Lonza Group AG LONN.SW	0	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	0	-	KR
UCB S.A. UCB.BR	0	-	BE

Empresa

Número de desdobramentos de ações

Multiplicador cumulativo

País